Legal & General Group’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.9K | Sell |
21,492
-222,486
| -91% | -$306K | ﹤0.01% | 2834 |
|
|
2025
Q4 | $393K | Sell |
243,978
-1,273
| -0.5% | -$2.67K | ﹤0.01% | 2478 |
|
|
2025
Q3 | $670K | Buy |
245,251
+221,972
| +954% | +$738K | ﹤0.01% | 2358 |
|
|
2025
Q2 | $84.7K | Buy |
23,279
+4,798
| +26% | +$13.2K | ﹤0.01% | 2656 |
|
|
2025
Q1 | $35.5K | Buy |
18,481
+352
| +2% | +$719 | ﹤0.01% | 2774 |
|
|
2024
Q4 | $34.4K | Sell |
18,129
-568
| -3% | -$986 | ﹤0.01% | 2855 |
|
|
2024
Q3 | $24.7K | Buy |
18,697
+730
| +4% | +$975 | ﹤0.01% | 2964 |
|
|
2024
Q2 | $18.1K | Buy |
+17,967
| New | +$22.2K | ﹤0.01% | 3065 |
|
|
2022
Q3 | – | Sell |
-13,943
| Closed | -$5K | – | 3454 |
|
|
2022
Q2 | $5K | Sell |
13,943
-103,276
| -88% | -$43.3K | ﹤0.01% | 3440 |
|
|
2022
Q1 | $84K | Buy |
117,219
+5,287
| +5% | +$11.3K | ﹤0.01% | 2906 |
|
|
2021
Q4 | $253K | Buy |
111,932
+4,887
| +5% | +$13.3K | ﹤0.01% | 2616 |
|
|
2021
Q3 | $308K | Buy |
107,045
+29,730
| +38% | +$84.9K | ﹤0.01% | 2561 |
|
|
2021
Q2 | $293K | Buy |
77,315
+43,113
| +126% | +$145K | ﹤0.01% | 2446 |
|
|
2021
Q1 | $116K | Buy |
34,202
+26
| +0.1% | +$94 | ﹤0.01% | 2577 |
|
|
2020
Q4 | $96K | Sell |
34,176
-325
| -0.9% | -$949 | ﹤0.01% | 2597 |
|
|
2020
Q3 | $87K | Sell |
34,501
-4,014
| -10% | -$35.2K | ﹤0.01% | 2524 |
|
|
2020
Q2 | $523K | Buy |
38,515
+17,356
| +82% | +$180K | ﹤0.01% | 2162 |
|
|
2020
Q1 | $161K | Sell |
21,159
-4,892
| -19% | -$38.1K | ﹤0.01% | 2316 |
|
|
2019
Q4 | $165K | Hold |
26,051
| – | – | ﹤0.01% | 2442 |
|
|
2019
Q3 | $102K | Buy |
26,051
+3,319
| +15% | +$14.2K | ﹤0.01% | 2512 |
|
|
2019
Q2 | $110K | Buy |
22,732
+5,938
| +35% | +$33.8K | ﹤0.01% | 2495 |
|
|
2019
Q1 | $137K | Hold |
16,794
| – | – | ﹤0.01% | 2410 |
|
|
2018
Q4 | $93K | Buy |
16,794
+9,279
| +123% | +$72.6K | ﹤0.01% | 2480 |
|
|
2018
Q3 | $66K | Hold |
7,515
| – | – | ﹤0.01% | 2643 |
|
|
2018
Q2 | $75K | Sell |
7,515
-744
| -9% | -$7.45K | ﹤0.01% | 2585 |
|
|
2018
Q1 | $79K | Sell |
8,259
-2,846
| -26% | -$39.8K | ﹤0.01% | 2551 |
|
|
2017
Q4 | $167K | Sell |
11,105
-414
| -4% | -$6.87K | ﹤0.01% | 2391 |
|
|
2017
Q3 | $225K | Buy |
11,519
+1,847
| +19% | +$28.4K | ﹤0.01% | 2304 |
|
|
2017
Q2 | $142K | Buy |
9,672
+714
| +8% | +$9.05K | ﹤0.01% | 2436 |
|
|
2017
Q1 | $83K | Sell |
8,958
-401
| -4% | -$3.92K | ﹤0.01% | 2648 |
|
|
2016
Q4 | $97K | Buy |
9,359
+5,037
| +117% | +$43.4K | ﹤0.01% | 2582 |
|
|
2016
Q3 | $38K | Hold |
4,322
| – | – | ﹤0.01% | 2643 |
|
|
2016
Q2 | $32K | Hold |
4,322
| – | – | ﹤0.01% | 2694 |
|
|
2016
Q1 | $39K | Buy |
4,322
+3,358
| +348% | +$27.2K | ﹤0.01% | 2511 |
|
|
2015
Q4 | $12K | Buy |
+964
| New | +$9.84K | ﹤0.01% | 2756 |
|
Other funds holding AKBA
VCM
VPM
Legal & General Group's AKBA Position: Q1 2026 in Review
Legal & General Group reduced its Akebia Therapeutics (AKBA) stake by 91% in Q1 2026, selling an estimated $306K and leaving 21,492 shares worth $29.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2834.
Legal & General Group first reported a position in AKBA in Q4 2015 and has held it in 35 quarters since. The position peaked at $670K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Legal & General Group held 21,492 shares of Akebia Therapeutics worth $29.9K as of Q1 2026.
- Legal & General Group sold 222,486 Akebia Therapeutics shares in Q1 2026, an estimated $306K.
- Akebia Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2834 holding.
- Legal & General Group first reported a position in Akebia Therapeutics in Q4 2015 and has held it in 35 quarters since.
- Legal & General Group's Akebia Therapeutics position peaked at $670K in Q3 2025.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.